Search

everythinglearnresearchcommunity

for

Search:↓

Nutrafol, a hair loss supplement, has limited and potentially biased research, with one study showing a 10% increase in hair count for women after 6 months but no significant results for men. The user concludes that cheaper, well-studied options like minoxidil may be more effective, especially for men, given the lack of evidence supporting Nutrafol.

A user is experiencing facial bloating from low-dose topical finasteride due to high estradiol levels and is seeking advice on using DIM to manage this issue, including dosage and brand recommendations.

User xEternex tries hair regrowth with daily broccoli sprouts, apple extract containing procyanidin b2, and microneedling. Others discuss potential issues with the experiment and share their experiences with vegetable consumption and hair growth.

The discussion revolves around the need for future oral DHT blockers for hair loss treatment that don't have the side effects of current options like Finasteride and Dutasteride. One user suggests that the future of hair loss treatment will likely be topical anti-androgens, as they can target hair follicles without affecting the entire system.

The post and conversation are about the role of the enzyme 3alpha-hydroxysteroid reductase in hair loss and the potential of compounds like procyanidin B2 and sulforaphane to boost its activity for hair regrowth. Further research is needed to develop effective treatments based on this theory.

New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.

The conversation discusses the progress and potential of hair cloning by Stemson Therapeutics, questioning if it will be realized in the next 5-10 years or if it's just false hope. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.

The progress of Phase I of HMI-115, a potential hair loss treatment, which consists of Minoxidil, finasteride, and RU58841. The estimated completion date is June.

The conversation is about optimism for new hair loss treatments like Stemson's bioengineering, osteopotin, SCUBE3, GT20029, and Verteprofin, and inquires about other notable treatments.

The user has tried RU58841, pyrilutamide, oral minoxidil combined with finasteride or dutasteride for hair loss. They are asking for new and exciting treatments.

TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.

Hair loss discussion includes Minoxidil, finasteride, and RU58841 treatments. Hope Medicine has a new CEO, possibly leading to HMI's termination.

The conversation discusses the effectiveness of reducing DHT for hair loss treatment and explores alternative approaches like reducing androgen receptor sensitivity. Specific treatments mentioned include finasteride, dutasteride, pyrilutamide (KX-826), GT20029, and RU58841.

23-year-old man tries finasteride, minoxidil, PRP, and dutasteride for hair loss. Recommends personalized routine and focusing on other life aspects.

The conversation discusses the approval of Kintor Pharmaceutical's AR-PROTAC (GT20029) for clinical trials in China for acne and androgenic alopecia. One user expresses optimism about new treatments being developed and seeks clarification on how the new drug works, specifically if it temporarily degrades the AR protein to reduce DHT sensitivity in hair follicles.

The conversation is about the availability of WINLEVI, a hair loss treatment, and the possibility of getting it compounded. The user is seeking information on when they can obtain the treatment.

Breezula® (Clascoterone) showed promising results in a Phase 2 trial for treating hair loss, being as effective as Propecia with no serious side effects. It might be released between 2021-2022, and a related acne treatment with the same active ingredient could be used in the meantime.

Dutasteride mesotherapy was not effective for hair regrowth, leading to consideration of oral or topical dutasteride. Oral dutasteride is suggested as more effective and cost-efficient than mesotherapy, with some users experiencing side effects from finasteride.

The conversation discusses hair loss treatments for a 30-year-old female, comparing red light therapy with minoxidil and finasteride. Concerns about hormonal impact and potential pregnancy are raised, with suggestions to consider spironolactone and microneedling, while emphasizing the importance of consulting a dermatologist.

AMP-303, a new injectable treatment for androgenetic alopecia, showed promising results in increasing hair count and density with minimal side effects. The treatment demonstrated significant hair regrowth and durability, offering new hope for those with hair loss.

Follicopeptide (FOL005) by Coegin Pharma will launch as a cosmetic hair growth treatment by Q2 2025, showing similar efficacy to finasteride. Users discuss the benefits and skepticism of releasing hair loss treatments as cosmetics rather than drugs.

RU58841 powder from a lab supplier was tested at a free drug testing service. The discussion includes using Minoxidil and finasteride for hair loss treatment.

The user discusses their long struggle with hair loss, considering various treatments like hair transplants, hair systems, and natural methods such as micro-needling, vitamin supplements, and a healthy lifestyle. They express concerns about side effects from drugs like finasteride and ultimately lean towards using a hair system for better appearance and confidence.

A user is participating in a phase 3 trial for Clascoterone, a topical acne medication that may stimulate hair growth, and will share results after 6 months. They will have a section of their hair shaved and marked with a tattoo for the study.

The conversation discusses the delay in the release of GT20029 for hair loss treatment and skepticism about its effectiveness. Participants mention other treatments like verteporfin and advancements in transplant procedures as more realistic options.

SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.

The conversation is about seeking new research on hair loss treatments beyond the commonly known ones like Minoxidil and Finasteride. Additions to the list of treatments include topical caffeine, alfatradiol, fluridil, stemoxydine, and upcoming treatments like TDM-105795 and verteporfin.

Potential cures for Androgenic Alopecia, specifically Kintor/HMI 115, CosmeRNA, Minoxidil and Finasteride.

Whether topical caffeine can be as effective for hair growth as minoxidil and finasteride, with various replies discussing the efficacy of these treatments and criticism of Dr. Huberman's research methods.